There is no single A1C number you need to qualify for Ozempic. The FDA approves it for adults with type 2 diabetes, and a type 2 diabetes diagnosis starts at an A1C of 6.5% or higher. But your actual ability to get a prescription depends on your doctor’s clinical judgment, and your ability to get it covered by insurance depends on your plan’s specific prior authorization rules.
What the FDA Actually Requires
Ozempic (semaglutide) is approved for three uses in adults: improving blood sugar control in type 2 diabetes, reducing the risk of major cardiovascular events in people with type 2 diabetes and heart disease, and protecting kidney function in people with type 2 diabetes and chronic kidney disease. All three indications require a diagnosis of type 2 diabetes. The label does not specify a minimum or maximum A1C threshold.
A type 2 diabetes diagnosis is made at an A1C of 6.5% or higher. So in the broadest sense, 6.5% is the floor. But that’s the diagnostic cutoff for diabetes itself, not a rule written into the Ozempic label.
What Insurance Companies Typically Require
This is where specific A1C numbers start to matter. Most insurers require prior authorization before they’ll cover Ozempic, and their criteria vary. UnitedHealthcare, for example, requires medical records confirming a type 2 diabetes diagnosis, which they define as an A1C of 6.5% or higher. Some plans set the bar higher, requiring an A1C of 7.0% or even 8.0% before approving a GLP-1 medication, particularly if they want to see that cheaper drugs like metformin were tried first.
Common prior authorization requirements include proof that you’ve tried and failed on metformin or another first-line medication, a confirmed type 2 diabetes diagnosis with lab values, and sometimes a minimum A1C that shows your blood sugar isn’t adequately controlled on your current treatment. If your A1C is already close to goal on metformin alone, some insurers will deny coverage on the basis that you don’t need it.
If your plan denies coverage, your doctor can often submit an appeal with additional clinical documentation. But this process takes time, and approval is never guaranteed.
A1C Isn’t Always the Deciding Factor
The 2025 American Diabetes Association guidelines recommend GLP-1 medications for people with type 2 diabetes who also have heart disease, heart failure, or chronic kidney disease, regardless of their A1C level. In these cases, the medication is being prescribed for organ protection, not just blood sugar control. A person with an A1C of 6.8% and established cardiovascular disease has a strong clinical case for Ozempic even though their blood sugar is only slightly above the diagnostic threshold.
This means your doctor may prescribe Ozempic based on your overall health picture rather than a single lab number. Weight, cardiovascular risk, kidney function, and how well you’ve responded to other medications all factor into the decision.
Prediabetes and Ozempic
If your A1C falls between 5.7% and 6.4%, you’re in the prediabetes range, and Ozempic is not FDA-approved for that purpose. Most insurers won’t cover it for prediabetes either, with a potential exception for people who also have obesity. The American Diabetes Association recommends lifestyle changes as the primary approach to reversing prediabetes.
People sometimes confuse Ozempic with Wegovy. Both contain semaglutide, but Wegovy is approved for weight management (based on BMI criteria), while Ozempic is approved specifically for type 2 diabetes. If you have prediabetes and are primarily looking for weight loss support, Wegovy has a separate set of eligibility criteria that don’t depend on A1C at all.
How Much Ozempic Lowers A1C
In the clinical trials that led to Ozempic’s approval, participants started with baseline A1C levels between 8.1% and 8.4%. These were people with meaningfully uncontrolled blood sugar, not borderline cases. Real-world data from over 1,200 patients on the 1.0 mg weekly dose showed an average A1C reduction of 1.4 percentage points among those who stayed on the medication consistently. More than half of patients saw their A1C drop by at least 1 full percentage point.
That reduction is significant. For someone starting at an A1C of 8.5%, dropping to 7.0% or below represents a major improvement in long-term diabetes outcomes. The effect is generally larger in people who start with higher A1C levels and smaller in those who are already closer to target.
What This Means in Practice
If you have a confirmed type 2 diabetes diagnosis (A1C of 6.5% or higher), you meet the basic medical criteria for an Ozempic prescription. Whether you actually get one depends on your doctor’s assessment of your full clinical picture and whether your insurance plan will cover it. The most common barrier isn’t the prescription itself but the prior authorization process, which often requires documentation that you’ve tried other medications first and that your blood sugar remains above a certain level.
Before your appointment, it helps to know your most recent A1C, what medications you’ve already tried, and whether you have any cardiovascular or kidney conditions. These details will determine both your clinical eligibility and the strength of any insurance appeal your doctor might need to file.